Under the category of the OTC/Nutraceutical products are listed the products which are sold without prescription. Members of Farmavita.net are invited to publish their out-license offers in this Category.

Description

Readily available is Tamoxifen, tablets 10-20 mg, bulk supply with license for use of the EU CTD Dossier. Registration is obtained in the reference member state in EU.
Offer is valid subject to confirmation, country by country. Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

 INDICATIONS AND USAGE
Metastatic Breast Cancer:

Tamoxifen is effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, Tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from Tamoxifen therapy.

Adjuvant Treatment of Breast Cancer:

Tamoxifen is indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some Tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes.

Tamoxifen is indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.

The estrogen and progesterone receptor values may help to predict whether adjuvant Tamoxifen therapy is likely to be beneficial.

Tamoxifenreduces the occurrence of contralateral breast cancer in patients receiving adjuvant Tamoxifen therapy for breast cancer.

Ductal Carcinoma in Situ (DCIS):

In women with DCIS, following breast surgery and radiation, Tamoxifen is indicated to reduce the risk of invasive breast cancer. The decision regarding therapy with Tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of NTamoxifen therapy.

Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patients with breast cancer.

Reduction in Breast Cancer Incidence in High Risk Women:

Tamoxifen is indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality.

Tamoxifen is indicated only for high-risk women. "High risk" is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer ³1.67%, as calculated by the Gail Model.

Examples of combinations of factors predicting a 5-year risk ³1.67% are:

Age 35 or older and any of the following combination of factors:

One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or
At least 2 first degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; or
LCIS

 

Age 40 or older and any of the following combination of factors:

One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or
At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or
One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia.

 

Age 45 or older and any of the following combination of factors:

At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or
One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more.

 

Age 50 or older and any of the following combination of factors:

At least 2 first degree relatives with a history of breast cancer; or
History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or
History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more.

 

Age 55 or older and any of the following combination of factors:

One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or
History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older.

 

Age 60 or older and:

5-year predicted risk of breast cancer ³1.67%, as calculated by the Gail Model.

 

For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-800-544-2007.

There are no data available regarding the effect of Tamoxifen on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2).

After an assessment of the risk of developing breast cancer, the decision regarding therapy with Tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of Tamoxifen therapy. In the NSABP P-1 trial, Tamoxifen treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk.

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 25

Advertiser details

Contact Advertiser

Add comment

 
 

Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favourites

Sorry, you need to register or login first.

Advert search

Recent adverts

Lokking for EU CTD Dossiers for traditional...
546 Views
Member of  Farmavita.Net from EU is looking to...
5451 Views
We are looking to acquire Azathioprine tablet...
5855 Views
I am looking for a good quality dossier with...
6590 Views
We offer for outlicensing European e-CTD...
9795 Views
Novel herbal based throat pastilles with...
1851 Views
We are looking for EU-CTD dossier...
8118 Views